BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical & Diagnostic

ABL Bio and GSK Sign Multi-Program Licensing Deal to Develop Neurodegenerative Therapies Using Grabody-B Platform

ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases - Programs will leverage ABL...

April 07, 2025 | News

Daiichi Sankyo and AstraZeneca’s ENHERTU Approved in EU for Earlier Treatment of HER2 Low and Ultralow Breast Cancer

Based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free surviv...

April 04, 2025 | News

Senhwa’s CX-4945 Shows Promising Disease Control and Durability in Refractory Basal Cell Carcinoma

Basal Cell Carcinoma CSR Highlights CX-4945 Monotherapy: Progression-free survival (PFS) exceeded 21 months in two patients. Optimal Treatment Res...

April 03, 2025 | News

Mabwell’s B7-H3-Targeting ADC 7MW3711 Enters Phase Ib/II Trial in China for Advanced Solid Tumors

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel B7-H3-targeting ADC (R&D code: 7MW3711) ha...

April 03, 2025 | News

Lunit Collaborates with U.S. National Cancer Institute to Advance AI-Driven Cancer Research

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a collaboration with the Nationa...

April 01, 2025 | News

Gene Solutions Achieves Landmark Validation for Asia’s First Clinically Proven Multi-Cancer Blood Test, SPOT-MAS

Gene Solutions, a leading biotech company in Asia, proudly announces a groundbreaking achievement in cancer early detection. Common cance...

March 27, 2025 | News

AnHorn Medicines Doses First Subject in U.S. Phase I Trial for AH-001, a First-in-Class Protein Degrader Targeting Hair Loss

AnHorn Medicines, a pioneering AI-driven new drug discovery company, is pleased to announce that, AH-001, a first-in-class protein degrader for androg...

March 27, 2025 | News

CStone Submits EMA Application to Expand Sugemalimab Use in Stage III Lung Cancer

CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, announced the submiss...

March 25, 2025 | News

Shanghai ArkBio Completes Phase III Trial of AK0901 for Pediatric ADHD in China

Shanghai Ark Biopharmaceutical Co., Ltd. announced the successful completion of the Phase III clinical study of AK0901, a novel drug for the treatment of a...

March 25, 2025 | News

Alamar Biosciences Launches NULISAseq Mouse Panel 120 to Power Precision Biomarker Discovery in Preclinical Research

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce the launch of the NULISAseq M...

March 26, 2025 | News

Sermonix and Regor Therapeutics Forge Strategic Alliance to Advance Targeted Therapies for Metastatic Breast Cancer

Sermonix Pharmaceuticals, a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mB...

March 25, 2025 | News

Menarini Group, Stemline, and VisualDx Join Forces to Boost Early Detection of BPDCN Using AI-Driven Skin Imaging

BPDCN is an aggressive hematologic malignancy with a historically poor prognosis VisualDx is a clinical decision support system used by more than 2,300 ...

March 21, 2025 | News

Telix Secures FDA Approval for Gozellix® to Expand PSMA-PET Imaging Access in Prostate Cancer

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administrat...

March 21, 2025 | News

Formosa Pharmaceuticals and Cipla Sign Multi-Regional Licensing Deal for Ophthalmic Suspension APP13007

Taiwan-based Formosa Pharmaceuticals announced an exclusive licensing agreement with Cipla Limited referred to as "Cipla" for the commercialization of clob...

March 19, 2025 | News

Stay Connected